Antibodies News and Research

RSS

mRNA booster vaccine confers strong protection against SARS-CoV-2 Omicron in cancer patients

A new preprint research paper posted to the medRxiv* server reports the induction of high neutralizing activity in these patients against the Omicron VOC with a booster dose.

5 Jan 2022

Scientists provide a structural framework for Omicron immune evasion and ACE2 receptor recognition

An interesting preprint research paper describes structural changes resulting from the multiple mutations found in the recent Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is the causative agent behind the coronavirus disease 2019 (COVID-19) pandemic. In addition, the research describes the consequent effects of these changes on Omicron’s infectivity and immune evasion capabilities.

5 Jan 2022

Transplant recipients benefit from a COVID-19 vaccine booster

A new preprint research paper posted to the medRxiv* server describes the reduction in humoral immunity in SOTR following vaccination, as well as the improvement with an additional dose of the vaccine.

4 Jan 2022

Time since COVID vaccination is a key driver of breakthrough Omicron infections

Published on the preprint medRxiv* server and awaiting peer review, the findings showed that the significant factor behind breakthrough Omicron infections is the timing from vaccination. The time between vaccination and breakthrough infections induced effective or cross-reactive neutralizing antibodies that neutralize Omicron after Alpha or Delta breakthrough infections.

4 Jan 2022

New study on NAbs against SARS-CoV-2 Omicron variant after vaccination or infection

A recent study suggests neutralizing antibody responses against variants of concern, including Omicron, differs significantly between vaccinated and naturally infected individuals. The research, posted to the medRxiv* preprint server, focused on vaccinated individuals who are pregnant — an understudied group in COVID-19 research.

4 Jan 2022

BNT162b2 provides low vaccine responders adequate anti-spike and neutralizing antibodies to prevent SARS-CoV-2

A new study, published on the medRxiv* preprint server, investigated the changes in SARS-CoV-2 antibody levels among HCWs after SARS-CoV-2 vaccination. The study also assessed whether low responders produced sufficient SARS-CoV-2 anti-spike and neutralizing antibodies.

4 Jan 2022

Scientists find that having one kind of autoimmune disease can lead to another

Researchers at the University of Colorado Anschutz Medical Campus have discovered that having one kind of autoimmune disease can lead to another.

4 Jan 2022

SARS-CoV-2 mRNA vaccine boosters crucial in maintaining neutralizing antibodies in HCPs

Researchers evaluate the effects of a third dose of the BNT162b2 mRNA vaccine on antibody titers and breakthrough infections in healthcare workers.

4 Jan 2022

Israeli study confirms drop in BNT162b2 efficacy after six months

Researchers determine whether BNT162b2 vaccination has become less efficient in preventing infection over time.

4 Jan 2022

Efficacy of antibodies induced by natural infection, vaccination, or both against SARS-CoV-2 Omicron and Beta variants

A study has demonstrated that antibodies induced by two-dose COVID-19 vaccination or natural infection exhibit very low neutralizing activity against the omicron variant of SARS-CoV-2.

4 Jan 2022

Study finds pan-sarbecovirus nanobodies can enhance development of super-immunity

A new study found that applying pan-sarbecovirus nanobodies shows a strong affinity toward all sarbecovirus clades and neutralized SARS-CoV-2 receptor binding domains

4 Jan 2022

Sino Biological Establishes New Location in Houston, Texas

Sino Biological, Inc. (“Sino Biological” or the “Company”), a biotechnology company listed on ChiNext (SZSE: 301047), provides biological research reagents and related technical contract research services, is pleased to announce its physical geographic expansion, adding a new location in Houston, Texas.

From Sino Biological Inc. 4 Jan 2022

Sino Biological Deposits Recombinant Omicron Proteins and Antibodies to BEI Resources

Sino Biological, Inc. (SZSE: 301047) has recently deposited reagents for the Omicron variant, including recombinant proteins to Spike and Nucleocapsid, and antibody products to BEI Resources, a central repository for reagents to support infectious disease research.

From Sino Biological Inc. 4 Jan 2022

SARS-CoV-2 spike T cell responses from vaccines or infection remain robust against Omicron

In a new study, a team of researchers from multi-national institutions discovered that 70-80% of CD4 and CD8 T cell responses to spike were consistent across research groups. Moreover, although having far more mutations, the magnitude of Omicron cross-reactive T cells was comparable to that of the Beta and Delta variants.

3 Jan 2022

Production of molecular probes of spike and subdomains for all SARS-CoV-2 variants

Researchers designed molecular probes of diverse SARS-CoV-2 variants and evaluated their antibody binding specificity.

3 Jan 2022

The impact of natural selection on sequence diversity in SARS-CoV-2

Recent genomic analysis demonstrates that the SARS-CoV-2 genome is under two distinct selective forces.

3 Jan 2022

Study finds critical metabolic vulnerability of diffuse large B cell lymphomas

Aggressive and relatively common lymphomas called diffuse large B cell lymphomas (DLBCLs) have a critical metabolic vulnerability that can be exploited to trick these cancers into starving themselves, according to a study from researchers at Weill Cornell Medicine and Cornell's Ithaca campus.

3 Jan 2022

Antibodies News and Research

mRNA booster vaccine confers strong protection against SARS-CoV-2 Omicron in cancer patients

Scientists provide a structural framework for Omicron immune evasion and ACE2 receptor recognition

Transplant recipients benefit from a COVID-19 vaccine booster

Time since COVID vaccination is a key driver of breakthrough Omicron infections

New study on NAbs against SARS-CoV-2 Omicron variant after vaccination or infection

BNT162b2 provides low vaccine responders adequate anti-spike and neutralizing antibodies to prevent SARS-CoV-2

Scientists find that having one kind of autoimmune disease can lead to another

SARS-CoV-2 mRNA vaccine boosters crucial in maintaining neutralizing antibodies in HCPs

Israeli study confirms drop in BNT162b2 efficacy after six months

Efficacy of antibodies induced by natural infection, vaccination, or both against SARS-CoV-2 Omicron and Beta variants

Study finds pan-sarbecovirus nanobodies can enhance development of super-immunity

Sino Biological Establishes New Location in Houston, Texas

Sino Biological Deposits Recombinant Omicron Proteins and Antibodies to BEI Resources

SARS-CoV-2 spike T cell responses from vaccines or infection remain robust against Omicron

Production of molecular probes of spike and subdomains for all SARS-CoV-2 variants

The impact of natural selection on sequence diversity in SARS-CoV-2

Study finds critical metabolic vulnerability of diffuse large B cell lymphomas

Omicron spike-specific binding antibodies attenuate disease, despite increasing transmission

SARS-CoV-2 Omicron variant highly resistant to vaccine-elicited and therapeutic antibodies

Humanized antibody shows strong neutralization ability against SARS-CoV-2 Delta variant

Antibodies eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo